ZYBT Stock Analysis: Buy, Sell, or Hold?
ZYBT - Zhengye Biotechnology Holding Limited Ordinary Shares
$0.65
-0.03 (-4.55%)
βΌ
5d:
-15.1%
30d:
-18.2%
90d:
-28.71%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 28, 2026
24d
Get Alerted When ZYBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR STABILIZATION: ZYBT is down 15.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
βΈοΈ WAIT FOR STABILIZATION: ZYBT is down 15.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ZYBT is currently trading at $0.65, which is considered oversold relative to its 30-day fair value range of $0.72 to $0.87.
Technical Outlook: Technically, ZYBT is showing sideways momentum. The price is currently testing key support at $0.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: ZYBT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYBT is showing sideways momentum. The price is currently testing key support at $0.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: ZYBT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.72 -
$0.87
Company Quality Score
52/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
41.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-4.5%)
Trading Range Analysis
30-Day Trading Range
$0.72 -
$0.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.78
Resistance Level
$0.89
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Revenue Growth (YoY)
-40.9%
Earnings Growth (YoY)
-79.6%
Profit Margin
-60.0%
Share & Embed Analysis
Last updated: July 03, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I⦠|
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp⦠|
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |